louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02210429: Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques
Official title: Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Pain
Pain, Postoperative
Keywords: Supraclavicular Block
Supraclavicular Catheter
Pediatric Anesthesia
Regional Anesthesia
Supracondylar Elbow Fracture
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Sponsor class: OTHER
First posted: 2014-08-06
Enrollment: 200
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: We hypothesize that patients who receive a supraclavicular block via Angiocath, placed intra-operatively and dosed post-operatively following neurologic examination, will have lower pain scores, lower use of intravenous morphine equivalents in the post-anesthesia care unit, and lower rates of intervention for post-operative nausea and vomiting. We also hypothesize that patients receiving this nerve block had the same rates of nerve damage as the patients who did not receive a block and that there will be no demonstrable safety concerns with this block.


Eligibility criteria: Inclusion Criteria:

* Age under 18
* Undergoing supracondylar fracture fixation in operating room

Exclusion Criteria:

* Incomplete or inaccessable chart data

Primary outcomes:
measure: Post-operative opioid use
timeFrame: 24 hours
Secondary outcomes:
measure: Anti-emetic drug use
timeFrame: 24 hours
measure: Incidence of nerve damage or compartment syndrome
timeFrame: 1 month
measure: Pain Score
timeFrame: 24 hours
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Ann & Robert H. Lurie Children's Hospital of Chicago
state: Illinois
Study officials:
affiliation: Ann & Robert H Lurie Children's Hospital of Chicago
name: Santhanam Suresh, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Suresh S, Sarwark JP, Bhalla T, Janicki J. Performing US-guided nerve blocks in the postanesthesia care unit (PACU) for upper extremity fractures: is this feasible in children? Paediatr Anaesth. 2009 Dec;19(12):1238-40. doi: 10.1111/j.1460-9592.2009.03182.x. No abstract available.
citation: Steinfeldt J, Robison T, Przybylo HJ. Placement of an US-guided supraclavicular block postoperatively in children: can we make this easy? Paediatr Anaesth. 2010 Aug;20(8):780-1. doi: 10.1111/j.1460-9592.2010.03355.x. No abstract available.
Clinical trial NCT03646929: Motor Evoked Potentials With Modified Facilitation Technique
Official title: Motor Evoked Potentials With Modified Facilitation Technique: Normative Data and Reliability in Healthy Individuals and Comparison of Sensitivity and Specificity With Standard Technique in Patients With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Keywords: facilitation technique
multimodal evoked potentials (mmEP) in multiple sclerosis
motor evoked potential (MEP) in multiple sclerosis
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2018-08-24
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Investigating the change in Test- Retest- reliability in healthy individuals when applying a modified easy to use facilitation technique compared to standard facilitation technique and analyzing sensitivity and specificity in patients with multiple sclerosis regarding detection of pathologic results


Eligibility criteria: Inclusion Criteria for healthy individuals:

* Ability to understand the purpose and risks of the study, provide signed and dated informed consent
* Between 18 and 65 year of age
* No neurologic or psychiatric comorbidity requiring continous treatment
* No previous damage of central nervous System

Inclusion Criteria for patients:

* Ability to understand the purpose and risks of the study, provide signed and dated informed consent
* Between 18 and 65 year of age
* patients with inflammatory diseases of the central nervous system (CNS) or multiple sclerosis appointed for routine MEP diagnostic at the Department of Clinical Neurophysiology, University Hospital Basel

Exclusion Criteria:

* Contraindication for measuring of motoric evoked potentials (MEP): metal implants (pacemaker, stents); known epilepsy oder previous epileptic fit
* Known disease of the peripheral nervous system (polyneuropathy)

Primary outcomes:
measure: Change in Test- Re-Test reliability when using modified facilitation technique (compared to standard facilitation technique) in healthy individuals
timeFrame: measuring time 2 (75 minutes) maximal 1 month later than measuring time 1 (75 minutes)
measure: comparison of sensitivity and specificity of modified facilitation technique and standard facilitation technique in patients with multiple sclerosis
timeFrame: 1 measuring time (90 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Dep. of Neurology and Clinical Neurophysiology , Hospital of the University of Basel
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Martin Hardmeier, PD Dr. med
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06258629: Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality
Official title: Resident of Clinical Pathology in Sohag Oncology Center
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Hematological Malignancies
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-02-14
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 60
Standard ages: CHILD
ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Control group of healthy individuals.
* Newly diagnosed cases of hematological malignancis.

Brief summary: Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality


Eligibility criteria: Inclusion Criteria:

* Newly diagnosed cases of hematological malignancis.

Exclusion Criteria:

* Known cases of hematological malignancies and on treatment.

Primary outcomes:
measure: Level of CD200 diagnostic marker assessed by flow cytometry
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Biondi A, Cazzaniga G. Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. Hematology Am Soc Hematol Educ Program. 2013;2013:612-9. doi: 10.1182/asheducation-2013.1.612.
citation: Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018 Apr 11;10(436):eaao3003. doi: 10.1126/scitranslmed.aao3003.
citation: Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, Di Raimondo F, Tedeschi A, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foa R. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013 Nov;98(11):1702-10. doi: 10.3324/haematol.2012.080432. Epub 2013 May 28.
citation: Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, Darley RL. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 2011 May;25(5):792-9. doi: 10.1038/leu.2011.1. Epub 2011 Jan 28.
Clinical trial NCT00604929: Effect of Nutrition on Muscle Protein Synthesis
Official title: The Effect of Carbohydrate and Protein Intake on Muscle Protein Synthesis During Endurance Exercise
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: muscle protein synthesis
whole-body protein breakdown
nutrition
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2008-01-30
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 28
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The present proposal is designed to examine the effect of carbohydrate and protein co-ingestion on muscle protein synthesis during endurance type exercise activities. We hypothesize that muscle protein synthesis is higher when protein is co-ingested during exercise.


Eligibility criteria: Inclusion Criteria:

* recreationally endurance trained

Exclusion Criteria:

* BMI \> 25 kg/m2
* Not physically active

Primary outcomes:
measure: Differences in muscle protein synthesis rates between carbohydrate and carbohydrate + protein.
timeFrame: 1 day
Secondary outcomes:
measure: Difference in whole-body protein synthesis and breakdown between carbohydrate and carbohydrate plus protein.
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
affiliation: Maastricht University
name: L van Loon, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01985529: A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD
Official title: A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2013-11-15
Enrollment: 19
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The effectiveness of clinic-based pulmonary rehabilitation in advanced Chronic Obstructive Pulmonary Disease (COPD) is well established, but few data exist for less severe patients treated in alternative settings. The purpose of this study was to investigate whether a novel, community-based exercise program was feasible and effective for patients with moderate COPD.


Eligibility criteria: Inclusion Criteria:

* patients with moderate COPD and self-reported exercise impairment

Exclusion Criteria:

* current smokers, pulmonary diseases other than COPD, use of supplemental oxygen, musculoskeletal disease that impaired exercise performance and unstable coronary artery disease or congestive heart failure

Primary outcomes:
measure: Endurance
timeFrame: 12 weeks
Secondary outcomes:
measure: Muscle Strength
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Westwood
country: United States
facility: UCLA
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Christopher Cooper, MD
role: STUDY_DIRECTOR
References:
citation: Amin S, Abrazado M, Quinn M, Storer TW, Tseng CH, Cooper CB. A controlled study of community-based exercise training in patients with moderate COPD. BMC Pulm Med. 2014 Aug 4;14:125. doi: 10.1186/1471-2466-14-125.
Clinical trial NCT03084029: The Neural Basis of Oxytocin's Effects on Empathy
Official title: The Neural Basis of Oxytocin's Effects on Empathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Healthy
Keywords: oxytocin
fMRI
empathy
Lead sponsor: University of Electronic Science and Technology of China
Sponsor class: OTHER
First posted: 2017-03-20
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: BASIC_SCIENCE

Brief summary: The main focus of this study is to examine oxytocin effects on behavioral and neural indices of empathy processing.

Detailed description: The neuropeptide oxytocin (OXT) has been demonstrated to modulate empathy in previous behavioural studies. The present study aims at replicating previous findings on OXT on empathy as well as to determine the neural basis of these effects.

In a between-subject, randomized double-blind design, subjects will be either administered intranasal OXT or placebo nasal spray (40 IU). 45 minutes after administration subjects will undergo (fMRI) tasks of empathic processing.

During the tasks subjects will be shown empathy inducing stimuli, and the behavioral and neural response in terms of cognitive, emotional and indirect emotional empathy will be assessed.

Before the administration of treatment, validated questionnaires assessing potential confounding variables, such as depression (Becks Depression Inventory (BDI)) or mood (Positive And Negative Affect Scale (PANAS)) will be administered to the subjects.

Eligibility criteria: Inclusion Criteria:

* Healthy subjects without past or current psychiatric or neurological disorders
* no smoking at least 12 hours before experiment
* no alcohol, coffee or other stimulant drinking at least 12 hours before experiment

Exclusion Criteria:

* mental implants
* pregnancy
* uterine cavity operations
* use of medication
* acute physical disorder

Primary outcomes:
measure: Neural processing of empathy as assessed using fMRI
timeFrame: 45-115 minutes after single dose administration
Secondary outcomes:
measure: Behavioral ratings of subjective experienced empathy processing
timeFrame: 45-115 minutes after single dose administration
Other outcomes:
Locations:
city: Chengdu
country: China
facility: School of Life Science and Technology,University of Electronic Science and Technology
state: Sichuan
Study officials:
affiliation: China,Sichuan, School of Life Science and Technology,University of Electronic Science and Technology
name: Keith Kendrick, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00571129: Endoscopic Dacryocystorhinostomy Prospective Research
Official title: Recovery After Endoscopic Dacryocystorhinostomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lacrimal Duct Obstruction
Keywords: Primary,silicone tube,revision,mitomycin C,endoscopic DCR
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
First posted: 2007-12-11
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: DCR with/ without tubes Revision DCR with/ without mitomycin
Primary purpose: TREATMENT

Brief summary: Endoscopic dacryocystorhinostomy (EN-DCR) is an effective procedure when treating saccal and postsaccal obstructions of the nasolacrimal pathway. The benefit of silicone tubing after DCR is still controversial. We conducted a prospective, randomized study in order to evaluate 1) the necessity of bicanalicular silicone tubes after primary EN-DCR, 2) efficacy of the perioperative Mitomycin C for the prevention of adheesion and re-stenosis of rhinostomy site in revision EN-DCR, 3) the subjective symptoms and QoL changes before and after DCR-operation.


Eligibility criteria: Inclusion Criteria:

* Adults (age \> 18), ASAI-III, and were scheduled for primary or revision lacrimal pathway surgery due to recurrent or chronic watering eyes or conjunctival discharge.
* Patients were excluded if they had previous nasolacrimal surgery, malignancy in the paranasal sinuses, nasal cavity, or lacrimal pathway, presaccal obstruction, pregnancy or lactation, or mental disability.

Exclusion Criteria:

* Malignancy in the paranasal sinuses, nasal cavity, or lacrimal pathway, presaccal obstruction, pregnancy or lactation, or mental disability.

Primary outcomes:
measure: The success rate after primary DCR with and without silicone tubes. The success rate after revisio DCR with and without Mitomycin C.
timeFrame: 5 years
Secondary outcomes:
measure: The EN-DCR operation influence on the patients subjective symptoms and QoL before and after operation.
timeFrame: 5 years
Other outcomes:
Locations:
city: Kuopio
country: Finland
facility: Kuopio University Hospital
state: North-Savo
Study officials:
affiliation: Kuopio University Hospital, Otorhinolaryngology
name: Juha Seppä, MD,PhD
role: STUDY_CHAIR
References:
citation: Penttila E, Hyttinen JM, Hytti M, Kauppinen A, Smirnov G, Tuomilehto H, Seppa J, Nuutinen J, Kaarniranta K. Upregulation of inflammatory genes in the nasal mucosa of patients undergoing endonasal dacryocystorhinostomy. Clin Ophthalmol. 2014 Apr 25;8:799-805. doi: 10.2147/OPTH.S50195. eCollection 2014.
Clinical trial NCT03195829: Feasibility Study of a Computerized Cognitive Stimulation
Official title: A Computerized Cognitive Stimulation Program in Elderly With Mild Cognitive Impairment: A Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mild Cognitive Impairment, So Stated
Keywords: Mild Cognitive Impairment
Computerized Cognitive Stimulation
Cognition
Psychosocial factors
Lead sponsor: Broca Hospital
Sponsor class: OTHER
First posted: 2017-06-22
Enrollment: 20
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled pilot study, single blind
Primary purpose: PREVENTION

Brief summary: This non-pharmacological interventional feasibility study evaluate a computerized cognitive stimulation program in elderly with mild cognitive impairment.

Detailed description: Involvement in social and leisure activities has been associated with a decreased risk of dementia in the elderly with Mild Cognitive Impairment (MCI). MCI is a crucial phase to prevent the worsening of cognitive decline in elderly at risk to develop dementia. These last years, the use of computerized training programs to enhance cognitive functioning showed positive and promising results. However, the effects on psychosocial factors still poorly documented in cognitive interventions in MCI. It seems essential to promote these factors involving social ties, group dynamic, the motivation, as factors that can contribute to enhance social life and cognitive functioning.

This feasibility study evaluated a computer-based cognitive stimulation in elderly with MCI and explore the effects on cognitive and psychosocial components.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Mild Cognitive Impairment
* Absence of history of alcohol or other substance consumption
* No engagement in other cognitive intervention program

Exclusion Criteria:

* Psychiatric and neurological disorders
* Conversion toward dementia during intervention
* Sensory and or motor deficit that could interfere with the use of computer tool

Primary outcomes:
measure: GROBER-BUSCHKE TEST
timeFrame: Baseline assessment before intervention, change from baseline at 3 months immediately after intervention
Secondary outcomes:
measure: Technologies Acceptation Questionnaire
timeFrame: Baseline assessment before intervention, change from baseline at 3 months immediately after intervention
Other outcomes:
Locations:
Study officials:
affiliation: Broca University Hospital
name: Anne-Sophie AR RIGAUD, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06049329: A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
Official title: Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0487-0111 in Japanese Participants With Obesity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Obesity
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2023-09-22
Enrollment: 36
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.


Eligibility criteria: Key inclusion criteria

* Male with both parents of Japanese descent
* Body mass index (BMI) between 25.0 and 34.9 kg/m\^2 (both inclusive). Body weight equal to or greater than 65.0 kg
* Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator

Key exclusion criteria

* Any disorder that in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
* Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator

Primary outcomes:
measure: Number of treatment emergent adverse events (TEAE)
timeFrame: From pre-dose on Day 1 until completion of the end of study visit Day 31
Secondary outcomes:
measure: AUC,MD; the area under the NNC0487-0111 plasma concentration-time curve after last multile dose
timeFrame: From pre-dose on Day 10 until Day 11 (24 hours post-dose)
measure: Cmax,MD; the maximum plasma concentration of NNC0487-0111 after last multiple dose
timeFrame: From pre-dose on Day 10 until completion of the end of study visit Day 31
measure: tmax,MD; the time of maximum plasma concentration of NNC0487-0111 after last multiple dose
timeFrame: From pre-dose on Day 10 until completion of the end of study visit Day 31
Other outcomes:
Locations:
city: Fukuoka
country: Japan
facility: Hakata Clinic
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References: